Henry Schein (HSIC) : Swedbank reduced its stake in Henry Schein by 3.93% during the most recent quarter end. The investment management company now holds a total of 1,885,554 shares of Henry Schein which is valued at $340,644,186 after selling 77,130 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on Jul 21, 2016.Henry Schein makes up approximately 2.75% of Swedbank’s portfolio.
Other Hedge Funds, Including , Ls Investment Advisors reduced its stake in HSIC by selling 575 shares or 5.95% in the most recent quarter. The Hedge Fund company now holds 9,086 shares of HSIC which is valued at $1,641,477. Henry Schein makes up approx 0.11% of Ls Investment Advisors’s portfolio.Vontobel Asset Management Inc reduced its stake in HSIC by selling 13,800 shares or 14.48% in the most recent quarter. The Hedge Fund company now holds 81,493 shares of HSIC which is valued at $14,759,197. Henry Schein makes up approx 0.12% of Vontobel Asset Management Inc’s portfolio.
Henry Schein opened for trading at $178.87 and hit $180.22 on the upside on Thursday, eventually ending the session at $179.28, with a gain of 0.15% or 0.27 points. The heightened volatility saw the trading volume jump to 2,46,511 shares. Company has a market cap of $14,713 M.
On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.